Immatics Biotechnologies Gmbh Stock News

TUEBINGEN, Germany & HOUSTON & NEW YORK--(BUSINESS WIRE)---- $BMY--Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics TCR Bispecific Program IMA401

Wall Street analysts expect Immatics (NASDAQ:IMTX) to announce earnings of ($0.32) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Immatics earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.31). The company is expected to issue its next earnings results on Tuesday, March 29th. According []

Immatics (NASDAQ:IMTX) Equities researchers at SVB Leerink dropped their FY2021 earnings estimates for shares of Immatics in a note issued to investors on Tuesday, November 16th. SVB Leerink analyst J. Chang now anticipates that the company will post earnings per share of ($1.65) for the year, down from their previous estimate of ($1.38). SVB []

Immatics (NASDAQ:IMTX) announced its earnings results on Monday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13), MarketWatch Earnings reports. Immatics stock traded up $0.06 during mid-day trading on Wednesday, hitting $12.25. The company had a trading volume of 122,171 shares, compared to its average []

Tuebingen , Germany and Houston, TX , November 16 , 20 2 1 Immatics N.V. (NASDAQ: IMTX; Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.

Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-r

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which missed the estimate of ($0.40).

Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redir

Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs).

BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell rec

Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell red